Streptomyces mutant strain and application of mutant strain

A technology of streptomyces and mutant bacteria, applied in the field of bioengineering, can solve the problems of high content of aureomycin A, low output of aureonomycin A, and many components of the original strain, and achieve high content, low content, and stable content change effect

Active Publication Date: 2021-08-20
ZHEJIANG UNIV OF TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The purpose of the present invention is to address the above-mentioned problems, such as many components of the original strain, high isolation cost in the later stage, and low aureus A production, to provide a Streptomyces mutant strain and its application. The mutant strain can produce fermented Produce aureotomycin, and the content of aureostatin A is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Streptomyces mutant strain and application of mutant strain
  • Streptomyces mutant strain and application of mutant strain
  • Streptomyces mutant strain and application of mutant strain

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Streptomyces mutated strain of the present invention is that the Streptomyces 891 that our laboratory separates from the mangrove deposits in the South China Sea is the original bacterial strain, and it is obtained through ultraviolet radiation mutagenesis. The mutagenesis method includes the following steps:

[0028] Step 1, inoculate the original Streptomyces 891 in the ISP 2 The agar medium was cultured at a constant temperature of 28°C;

[0029] Step 2, select the spores cultivated in step 1, add physiological saline, scrape off the spores with an inoculation loop, and adjust the concentration of the spore suspension to 10 with a hemocytometer. 6 / mL;

[0030] Step 3, the spore suspension prepared in step 2 is irradiated with ultraviolet light for 30s, 60s, 90s, 120s, 150s, 180s, 210s, 300s, then diluted and coated on ISP 2 In the agar medium, culture in the dark for 6-7 days, according to the growth of a single colony on the isolated plate, and using the blank as...

Embodiment 2

[0054] Mutant strain 891-B6 is produced aureostatin stability analysis, comprises the following steps:

[0055] Step 1, inserting the mutant strain 891-B6 into ISP 2 After the agar medium is activated and the seeds are cultivated, the seed solution is obtained;

[0056] Step 2, inoculating the seed liquid into a fermentation medium to carry out fermentation culture to obtain a fermentation liquid.

[0057] ISP mentioned in step 1 2 The composition of the agar medium is: 4.0g / L glucose, 4.0g / L yeast extract, 10.0g / L malt extract, 20.0g / L agar powder, pH 7.0, sterilized at 121°C for 20min.

[0058] The temperature of the seed cultivation in step 1 is 28° C., the rotational speed of the seed cultivation is 200 rpm, and the time of the seed cultivation is 48-72 hours.

[0059] The inoculum amount of the seed solution in step 2 is 5%-10% (V / V).

[0060] The composition of the fermentation medium described in step 2 is: 5.0g / L starch, 20.0g / L glucose, 10.0g / L soybean powder, 2.0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a streptomyces mutant strain and application of the mutant strain. The streptomyces mutant strain is named as streptomyces sp., the strain number is 891-B6, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.21775. The mutant strain 891-B6 is obtained by taking streptomyces 891 as an original strain, performing ultraviolet mutagenesis and performing morphological screening. The content of aureomycin A in a fermentation product of the mutant strain 891-B6 of the invention is 17.44% higher than the content of aureomycin A in a fermentation product of an original strain, the content of the active ingredient aureomycin A in the aureomycin produced by the mutant strain 891-B6 is high, the content of the inactive ingredient aureomycin B is remarkably reduced, and the content of the inactive component aureomycin C is stable and unchanged. Meanwhile, the mutant strain 891-B6 provided by the invention is good in hereditary stability, and the aureomycin A production level is equivalent to that of the first generation after the mutant strain 891-B6 is transferred to the third generation; and the mutant strain 891-B6 can be applied to industrial production of the aureomycin.

Description

technical field [0001] The invention relates to the technical field of bioengineering, in particular to a Streptomyces mutant strain and its application. Background technique [0002] Chrysomycin is a class of glycoside compounds with a benzonaphthyrone structure. It was first discovered in 1955 from Streptomyces strain A-419 and later isolated from several other strains of Streptomyces. Biological experiments show that these compounds have significant anti-phage, anti-bacterial and anti-tumor activities. [0003] [0004] In recent years, studies have shown that aureomycin A (structural formula shown in formula I) has a strong inhibitory effect on drug-resistant pathogens including Mycobacterium tuberculosis + Bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) have a significant antibacterial effect. Therefore, the lead compound has great potential to be developed as a new therapeutic drug for treating infectious diseases caused by drug-resistant patho...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N1/20C12P17/16C12R1/465
CPCC12N1/20C12P17/162
Inventor 章华伟吕孙燕唐宇琪祝王婕王鸿
Owner ZHEJIANG UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products